What is Evoke Pharma Inc's earnings per share (EPS)?

Evoke Pharma Inc (EVOK) reported diluted earnings per share of $-2.81 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Evoke Pharma Inc Financials

EVOK

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Evoke Pharma Inc (EVOK) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 40/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Evoke Pharma Inc has an operating margin of -50.8%, meaning the company retains $-51 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -143.4% the prior year.

Growth

100

Evoke Pharma Inc's revenue surged 97.8% year-over-year to $10.2M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Evoke Pharma Inc carries a low D/E ratio of 1.49, meaning only $1.49 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 72/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Evoke Pharma Inc's current ratio of 1.66 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 29/100, which could limit financial flexibility.

Returns

Evoke Pharma Inc generates a -76.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.

Piotroski F-Score Weak

2/9

Evoke Pharma Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

1.02x

For every $1 of reported earnings, Evoke Pharma Inc generates $1.02 in operating cash flow (-$5.5M OCF vs -$5.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-10.4x

Evoke Pharma Inc earns $-10.4 in operating income for every $1 of interest expense (-$5.2M vs $501K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$10.2M

YoY+97.8%

Evoke Pharma Inc generated $10.2M in revenue in fiscal year 2024. This represents an increase of 97.8% from the prior year.

EBITDA

N/A

Net Income

-$5.4M

YoY+31.3%

Evoke Pharma Inc reported -$5.4M in net income in fiscal year 2024. This represents an increase of 31.3% from the prior year.

EPS (Diluted)

$-2.81

Evoke Pharma Inc earned $-2.81 per diluted share (EPS) in fiscal year 2024. This represents an increase of 90.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$13.6M

YoY+186.9%

5Y CAGR+19.1%

10Y CAGR-0.4%

Evoke Pharma Inc held $13.6M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

Evoke Pharma Inc had 1M shares outstanding in fiscal year 2024. This represents an increase of 433.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-50.8%

YoY+92.7pp

Evoke Pharma Inc's operating margin was -50.8% in fiscal year 2024, reflecting core business profitability. This is up 92.7 percentage points from the prior year.

Net Margin

-52.2%

YoY+98.2pp

Evoke Pharma Inc's net profit margin was -52.2% in fiscal year 2024, showing the share of revenue converted to profit. This is up 98.2 percentage points from the prior year.

Return on Equity

-76.0%

5Y CAGR+86.6pp

10Y CAGR+68.1pp

Evoke Pharma Inc's ROE was -76.0% in fiscal year 2024, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$16K

YoY-91.0%

5Y CAGR-65.7%

10Y CAGR-47.4%

Evoke Pharma Inc invested $16K in research and development in fiscal year 2024. This represents a decrease of 91.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

EVOK Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$10.2M+97.8%	$5.2M+106.5%	$2.5M+55.0%	$1.6M+6929.0%	$23K	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$16K-91.0%	$182K-39.5%	$301K-49.1%	$590K-91.0%	$6.6M+91.9%	$3.4M
SG&A Expenses	$15.1M+23.3%	$12.2M+27.1%	$9.6M+8.7%	$8.9M+37.7%	$6.4M+72.0%	$3.7M
Operating Income	-$5.2M+30.0%	-$7.4M+4.6%	-$7.8M+4.5%	-$8.2M+37.5%	-$13.0M-82.4%	-$7.2M
Interest Expense	$501K+0.3%	$500K0.0%	$500K0.0%	$500K+342.5%	$113K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$5.4M+31.3%	-$7.8M-45.6%	-$5.4M+37.3%	-$8.5M+35.1%	-$13.2M-84.6%	-$7.1M
EPS (Diluted)	$-2.81	$-27.97	$-2.62+17.6%	$-3.18	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	$4.3M+14.2%	$3.8M+21.8%	$3.1M-6.9%	$3.3M+24.6%	$2.7M+4.0%	$2.6M+47.0%	$1.7M+3.5%	$1.7M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$5K-36.8%	$8K-80.3%	$43K	$0-100.0%	$12K	$0-100.0%	$5K	N/A
SG&A Expenses	$5.3M+3.5%	$5.1M+19.5%	$4.3M-2.0%	$4.4M+14.6%	$3.8M+2.4%	$3.7M+18.9%	$3.1M-9.8%	$3.5M
Operating Income	-$1.1M+27.0%	-$1.6M-19.8%	-$1.3M-9.1%	-$1.2M+7.2%	-$1.3M-5.1%	-$1.2M+18.5%	-$1.5M+20.5%	-$1.9M
Interest Expense	$126K+1.1%	$125K+1.1%	$123K-2.2%	$126K0.0%	$126K+1.1%	$125K0.0%	$125K-1.1%	$126K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.2M+26.4%	-$1.6M-20.3%	-$1.3M-9.5%	-$1.2M+9.1%	-$1.3M-3.6%	-$1.3M+19.8%	-$1.6M+30.6%	-$2.3M
EPS (Diluted)	$-0.45+27.4%	$-0.62-21.6%	$-0.51	N/A	$-0.94-1.1%	$-0.93	$-2.09	N/A

EVOK Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$17.5M+147.8%	$7.1M-40.4%	$11.9M+12.1%	$10.6M+12.1%	$9.4M+47.5%	$6.4M
Current Assets	$17.2M+152.5%	$6.8M-41.8%	$11.7M+11.0%	$10.6M+13.8%	$9.3M+48.6%	$6.2M
Cash & Equivalents	$13.6M+186.9%	$4.7M-51.9%	$9.8M+7.6%	$9.1M+13.3%	$8.1M+42.5%	$5.7M
Inventory	$445K-7.6%	$482K+66.5%	$289K+56.0%	$186K-21.5%	$236K	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$10.5M+8.6%	$9.6M+24.2%	$7.8M+10.7%	$7.0M-44.5%	$12.6M+527.7%	$2.0M
Current Liabilities	$10.4M+7.6%	$9.6M+483.1%	$1.7M+17.7%	$1.4M-81.3%	$7.5M+274.0%	$2.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$7.0M+372.8%	-$2.6M-163.2%	$4.1M+14.9%	$3.6M+210.6%	-$3.2M-173.4%	$4.4M
Retained Earnings	-$128.8M-4.3%	-$123.4M-6.7%	-$115.6M-7.7%	-$107.4M-8.6%	-$98.9M-15.3%	-$85.7M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$15.6M-2.6%	$16.1M-1.9%	$16.4M-6.5%	$17.5M+23.8%	$14.2M+16.6%	$12.1M-2.6%	$12.5M+76.2%	$7.1M
Current Assets	$15.5M-2.5%	$15.9M-1.8%	$16.2M-5.8%	$17.2M+22.8%	$14.0M+15.7%	$12.1M-2.6%	$12.5M+82.4%	$6.8M
Cash & Equivalents	$11.6M-4.0%	$12.1M-4.5%	$12.6M-7.2%	$13.6M+19.9%	$11.3M+23.5%	$9.2M-5.4%	$9.7M+104.7%	$4.7M
Inventory	$600K-6.5%	$642K+20.6%	$532K+19.6%	$445K-9.8%	$493K-9.4%	$545K-7.5%	$589K+22.2%	$482K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$12.3M+5.1%	$11.7M+10.9%	$10.5M+0.5%	$10.5M+7.3%	$9.8M+3.1%	$9.5M+5.7%	$9.0M-7.2%	$9.6M
Current Liabilities	$12.2M+5.3%	$11.6M+11.2%	$10.5M+0.7%	$10.4M+6.3%	$9.8M+3.1%	$9.5M+5.7%	$9.0M-7.2%	$9.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.4M-23.1%	$4.4M-25.1%	$5.8M-17.0%	$7.0M+60.4%	$4.4M+64.6%	$2.7M-23.8%	$3.5M+235.6%	-$2.6M
Retained Earnings	-$132.8M-0.9%	-$131.7M-1.2%	-$130.1M-1.0%	-$128.8M-0.9%	-$127.6M-1.0%	-$126.3M-1.0%	-$125.0M-1.3%	-$123.4M

EVOK Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$5.5M-9.5%	-$5.0M+24.4%	-$6.6M+46.6%	-$12.4M-86.3%	-$6.6M-15.1%	-$5.8M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$14.3M+12100.3%	-$119K-101.6%	$7.3M-45.7%	$13.4M+48.6%	$9.0M+47.9%	$6.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$522K+7.6%	-$565K+43.4%	-$998K+19.6%	-$1.2M-51.5%	-$819K+0.2%	-$821K+68.2%	-$2.6M-133.2%	-$1.1M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$39K	$0-100.0%	$25K-99.3%	$3.5M+17.4%	$3.0M+907.8%	$296K-96.1%	$7.5M	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

EVOK Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-50.8%+92.7pp	-143.4%+166.9pp	-310.4%+193.4pp	-503.8%+56174.5pp	-56678.3%	N/A
Net Margin	-52.2%+98.2pp	-150.4%+62.9pp	-213.4%+314.3pp	-527.7%+56616.9pp	-57144.5%	N/A
Return on Equity	-76.0%	N/A	-131.0%+109.1pp	-240.2%	N/A	-162.7%
Return on Assets	-30.6%+79.7pp	-110.2%-65.1pp	-45.2%+35.6pp	-80.8%+58.7pp	-139.4%-28.0pp	-111.4%
Current Ratio	1.66+1.0	0.71-6.4	7.08-0.4	7.51+6.3	1.23-1.9	3.10
Debt-to-Equity	1.49+5.2	-3.74-5.6	1.90-0.1	1.97+5.9	-3.93-4.4	0.46
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-26.6%+15.0pp	-41.5%+0.7pp	-42.3%-6.2pp	-36.1%+12.4pp	-48.4%-0.5pp	-48.0%+38.5pp	-86.5%+26.1pp	-112.6%
Net Margin	-27.0%+14.9pp	-41.9%+0.5pp	-42.4%-6.4pp	-36.0%+13.4pp	-49.5%+0.2pp	-49.7%+41.4pp	-91.0%+44.7pp	-135.8%
Return on Equity	-34.4%+1.5pp	-35.9%-13.5pp	-22.4%-5.4pp	-17.0%+13.0pp	-29.9%+17.6pp	-47.5%-2.4pp	-45.2%	N/A
Return on Assets	-7.4%+2.4pp	-9.8%-1.8pp	-8.0%-1.2pp	-6.8%+2.5pp	-9.3%+1.2pp	-10.4%+2.3pp	-12.7%+19.5pp	-32.2%
Current Ratio	1.27-0.1	1.37-0.2	1.55-0.1	1.66+0.2	1.44+0.2	1.28-0.1	1.39+0.7	0.71
Debt-to-Equity	3.65+1.0	2.67+0.9	1.80+0.3	1.49-0.7	2.23-1.3	3.55+1.0	2.56+6.3	-3.74
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Biofrontera Inc BFRI

$10.7M

Sonoma Pharmaceu SNOA

$4.2M

Sunshine Biopharma Inc SBFM

$5.4M

Im Cannabis Corp IMCC

$1.8M

China Pharma CPHI

$3.2M

Frequently Asked Questions

What is Evoke Pharma Inc's annual revenue?

Evoke Pharma Inc (EVOK) reported $10.2M in total revenue for fiscal year 2024. This represents a 97.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Evoke Pharma Inc's revenue growing?

Evoke Pharma Inc (EVOK) revenue grew by 97.8% year-over-year, from $5.2M to $10.2M in fiscal year 2024.

Is Evoke Pharma Inc profitable?

No, Evoke Pharma Inc (EVOK) reported a net income of -$5.4M in fiscal year 2024, with a net profit margin of -52.2%.

What is Evoke Pharma Inc's operating margin?

Evoke Pharma Inc (EVOK) had an operating margin of -50.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Evoke Pharma Inc's net profit margin?

Evoke Pharma Inc (EVOK) had a net profit margin of -52.2% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Evoke Pharma Inc's return on equity (ROE)?

Evoke Pharma Inc (EVOK) has a return on equity of -76.0% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Evoke Pharma Inc's operating cash flow?

Evoke Pharma Inc (EVOK) generated -$5.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Evoke Pharma Inc's total assets?

Evoke Pharma Inc (EVOK) had $17.5M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Evoke Pharma Inc spend on research and development?

Evoke Pharma Inc (EVOK) invested $16K in research and development during fiscal year 2024.

How many shares does Evoke Pharma Inc have outstanding?

Evoke Pharma Inc (EVOK) had 1M shares outstanding as of fiscal year 2024.

What is Evoke Pharma Inc's current ratio?

Evoke Pharma Inc (EVOK) had a current ratio of 1.66 as of fiscal year 2024, which is generally considered healthy.

What is Evoke Pharma Inc's debt-to-equity ratio?

Evoke Pharma Inc (EVOK) had a debt-to-equity ratio of 1.49 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Evoke Pharma Inc's return on assets (ROA)?

Evoke Pharma Inc (EVOK) had a return on assets of -30.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Evoke Pharma Inc's cash runway?

Based on fiscal year 2024 data, Evoke Pharma Inc (EVOK) had $13.6M in cash against an annual operating cash burn of $5.5M. This gives an estimated cash runway of approximately 30 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Evoke Pharma Inc's Piotroski F-Score?

Evoke Pharma Inc (EVOK) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Evoke Pharma Inc's earnings high quality?

Evoke Pharma Inc (EVOK) has an earnings quality ratio of 1.02x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Evoke Pharma Inc cover its interest payments?

Evoke Pharma Inc (EVOK) has an interest coverage ratio of -10.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Evoke Pharma Inc?

Evoke Pharma Inc (EVOK) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.